HOLX Stock Overview
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$70.63|
|52 Week High||US$85.00|
|52 Week Low||US$60.10|
|1 Month Change||-8.53%|
|3 Month Change||-4.05%|
|1 Year Change||-6.70%|
|3 Year Change||57.55%|
|5 Year Change||74.05%|
|Change since IPO||2,854.46%|
Recent News & Updates
Is Hologic (NASDAQ:HOLX) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|HOLX||US Medical Equipment||US Market|
Return vs Industry: HOLX underperformed the US Medical Equipment industry which returned -0.9% over the past year.
Return vs Market: HOLX underperformed the US Market which returned 6.6% over the past year.
|HOLX Average Weekly Movement||3.9%|
|Medical Equipment Industry Average Movement||8.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: HOLX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: HOLX's weekly volatility (4%) has been stable over the past year.
About the Company
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus.
Hologic Fundamentals Summary
|HOLX fundamental statistics|
Is HOLX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HOLX income statement (TTM)|
|Cost of Revenue||US$1.56b|
Last Reported Earnings
Sep 25, 2021
Next Earnings Date
Feb 02, 2022
|Earnings per share (EPS)||7.45|
|Net Profit Margin||33.23%|
How did HOLX perform over the long term?See historical performance and comparison
Is Hologic undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HOLX ($70.63) is trading below our estimate of fair value ($100.75)
Significantly Below Fair Value: HOLX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HOLX is good value based on its PE Ratio (9.5x) compared to the US Medical Equipment industry average (46.2x).
PE vs Market: HOLX is good value based on its PE Ratio (9.5x) compared to the US market (16.7x).
Price to Earnings Growth Ratio
PEG Ratio: HOLX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: HOLX is overvalued based on its PB Ratio (4.2x) compared to the US Medical Equipment industry average (3.4x).
How is Hologic forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HOLX's earnings are forecast to decline over the next 3 years (-44.5% per year).
Earnings vs Market: HOLX's earnings are forecast to decline over the next 3 years (-44.5% per year).
High Growth Earnings: HOLX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: HOLX's revenue is expected to decline over the next 3 years (-6.4% per year).
High Growth Revenue: HOLX's revenue is forecast to decline over the next 3 years (-6.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HOLX's Return on Equity is forecast to be low in 3 years time (17.8%).
How has Hologic performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HOLX has high quality earnings.
Growing Profit Margin: HOLX's current net profit margins (33.2%) are higher than last year (29.4%).
Past Earnings Growth Analysis
Earnings Trend: HOLX's earnings have grown significantly by 35.2% per year over the past 5 years.
Accelerating Growth: HOLX's earnings growth over the past year (68.8%) exceeds its 5-year average (35.2% per year).
Earnings vs Industry: HOLX earnings growth over the past year (68.8%) exceeded the Medical Equipment industry 51.2%.
Return on Equity
High ROE: HOLX's Return on Equity (44.3%) is considered outstanding.
How is Hologic's financial position?
Financial Position Analysis
Short Term Liabilities: HOLX's short term assets ($3.2B) exceed its short term liabilities ($1.3B).
Long Term Liabilities: HOLX's short term assets ($3.2B) do not cover its long term liabilities ($3.4B).
Debt to Equity History and Analysis
Debt Level: HOLX's net debt to equity ratio (44.1%) is considered high.
Reducing Debt: HOLX's debt to equity ratio has reduced from 156% to 71.9% over the past 5 years.
Debt Coverage: HOLX's debt is well covered by operating cash flow (76.8%).
Interest Coverage: HOLX's interest payments on its debt are well covered by EBIT (27x coverage).
What is Hologic current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HOLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HOLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HOLX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HOLX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HOLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Steve MacMillan (57 yo)
Mr. Stephen P. MacMillan, also known as Steve, has been the Chairman of the Board at Hologic Inc. since June 17, 2015 and its Chief Executive Officer and President since December 9, 2013. Mr. MacMillan ser...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD14.75M) is about average for companies of similar size in the US market ($USD11.42M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Experienced Management: HOLX's management team is considered experienced (4.2 years average tenure).
Experienced Board: HOLX's board of directors are considered experienced (8.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: HOLX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hologic, Inc.'s employee growth, exchange listings and data sources
- Name: Hologic, Inc.
- Ticker: HOLX
- Exchange: NasdaqGS
- Founded: 1985
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$17.750b
- Shares outstanding: 251.30m
- Website: https://www.hologic.com
Number of Employees
- Hologic, Inc.
- 250 Campus Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/21 23:34|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.